Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 18,775

Document Document Title
WO/2010/136508A2
The present invention describes an antigen-binding construct comprising a first agent which binds to a stem cell specific marker molecule and a second agent which binds to a tissue specific marker molecule. In particular, the invention d...  
WO/2010/137349A1
Disclosed is a compound which enhances the activity of neurotrophic factors and exerts a protective action on nerve cells. Specifically disclosed is a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a s...  
WO/2010/136508A3
The present invention describes an antigen-binding construct comprising a first agent which binds to a stem cell specific marker molecule and a second agent which binds to a tissue specific marker molecule. In particular, the invention d...  
WO/2010/134047A3
The present invention relates to a pharmaceutical solution comprising isotretinoin or salts thereof. The present invention further relates to the processes for preparing such compositions.  
WO/2010/132982A1
It is reported herein that certain muscle diseases and conditions, including forms of muscular dystrophy, are characterized by impaired insulin-dependent signaling in the muscle tissue, in essence, a form of insulin resistance. The prese...  
WO/2010/131712A1
Disclosed are a therapeutic pharmaceutical agent for diseases associated with the decrease in the function of GNE protein, a food composition, and a food additive. The therapeutic pharmaceutical agent is characterized by comprising a com...  
WO/2010/131382A1
Disclosed is a muscle repair promoter for local administration, which comprises a granulocyte-colony stimulating factor (G-CSF) as an active ingredient. The muscle repair promoter can exhibit the efficacy thereof at a small dose particul...  
WO/2010/130799A3
The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterised in that said method includes the following consecutive steps: a) mixing the active substa...  
WO/2010/130799A2
The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterised in that said method includes the following consecutive steps: a) mixing the active substa...  
WO/2010/129273A2
The present invention relates to the use of butaclamol and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.  
WO/2010/129406A3
The present invention relates to use of the interaction of myostatin with the activin type II receptors, and more specifically to use of soluble ACVR2 to increase muscle growth in a subject. As such, methods of increasing muscle mass in ...  
WO/2010/128243A1
The present invention relates to a method for preparing a concentrated spinach extract in a liquid or dry form and having a polyphenol titer greater than or equal to 50%, including a step of purifying a raw spinach extract in a liquid fo...  
WO/2010/129406A2
The present invention relates to use of the interaction of myostatin with the activin type II receptors, and more specifically to use of soluble ACVR2 to increase muscle growth in a subject. As such, methods of increasing muscle mass in ...  
WO/2010/129273A3
The present invention relates to the use of butaclamol and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.  
WO/2010/126104A1
Disclosed is a novel pyridazinone compound having an activity of inhibiting P2X7 receptor that is a kind of purine receptor, which is useful in preventing, treating or ameliorating diseases relating to inflammation or immunity. Specifica...  
WO/2010/124365A1
There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells,...  
WO/2010/125271A1
The invention relates to a gas mixture that contains nitrous oxide (N2O) for use as a breathable drug for the treatment of chronic pain in a mammal, in particular a pain from neuropathic, iatrogenic, dysfunctional or inflammatory origin,...  
WO/2010/125348A1
The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertat...  
WO/2010/126167A1
Disclosed are: a compound represented by formula (I), or a salt, solvate or physiologically functional derivative thereof; and a pharmaceutical composition comprising the compound or the salt, solvate or physiologically functional deriva...  
WO/2010/124520A1
The pharmaceutical compositions for treating abnormal energy metabolism, comprising a) medicines for promoting oxidation of fatty acid or derivatives thereof, particularly levocarnitine, and b) medicines for promoting oxidation of glucos...  
WO/2010/125799A1
Disclosed is a compound represented by formula (I), which inhibits the action of PI3K, controls a number of biological processes, such as the growth, differentiation, survival, proliferation, migration and metabolism of cells, and, there...  
WO/2010/121324A1
The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and ...  
WO/2010/123243A2
The present invention relates to a composition containing a testis extract for treating or preventing diseases. More particularly, a testis extract, which is a natural substance obtained by separating sex hormones containing anabolic ste...  
WO/2010/123243A3
The present invention relates to a composition containing a testis extract for treating or preventing diseases. More particularly, a testis extract, which is a natural substance obtained by separating sex hormones containing anabolic ste...  
WO/2010/119875A1
Disclosed is a fused pyrrolopyridine derivative which is useful as an active ingredient for a pharmaceutical composition, in particular a pharmaceutical composition for prevention or treatment of diseases that are caused by undesirable c...  
WO/2010/118675A1
The present invention reveals a new use of neferine. Neferine regulates M8 and V1 subtype of transient receptor potential ion channel (TRPM8 and TRPV1), respectively, in mammals, including humans, and can be used for preparing medicament...  
WO/2010/118699A1
High purified (2β,3α,5α,16β,17β) -2-(4-morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol (formula III) or composition containing it and their use in preparing rocuronium bromide (formula I) are disclosed.  
WO/2010/121225A2
The invention provides methods for the treatment or amelioration of disorders associated with undesired activity of protein kinase CK2, using compounds of Formula (I) that are potent, selective inhibitors of CK2, and pharmaceutical compo...  
WO/2010/121225A3
The invention provides methods for the treatment or amelioration of disorders associated with undesired activity of protein kinase CK2, using compounds of Formula (I) that are potent, selective inhibitors of CK2, and pharmaceutical compo...  
WO/2010/116673A1
Disclosed are a novel mitochondrial function-improving agent and a novel PGC-1α expression inducer. Specifically disclosed are a mitochondrial function-improving agent and a PGC-1α expression inducer, each of which comprises a lysine-s...  
WO/2010/113225A1
The present invention provides a novel transdermal patch containing high concentration of riluzole and being able to administer transdermally and quantitatively the drug to the ALS patients having difficulties taking the drug orally. Fur...  
WO/2010/112093A1
Compounds of formula (I), wherein R1, R2, R3, X and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/112091A1
Compounds of formula (I) wherein R1, R2, R3, X, and Y are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/112092A1
Compounds of formula (I) wherein R1, R2, R3, R4, L1, and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/113834A1
Disclosed is a novel and excellent method for preventing and/or treating cannabinoid-2 receptor-related diseases, which is based on an agonist action on cannabinoid-2 receptors. Specifically disclosed is a heterocyclic derivative mainly ...  
WO2010110440A1
Disclosed is a prophylactic and/or therapeutic agent for cognitive impairment including dementia of the Alzheimer type, which comprises 2-methyl-2-[(4-{(1E)-3-[2-(4-methylbenzoyl)- 1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propionic acid ...  
WO/2010/109386A1
The invention relates to a method for the industrial purification of biologically active phyctotoxins. According to said method, an adequate quantity of a phycotoxin source is provided; if the source of phycotoxins is a pellet, it is lys...  
WO/2010/108843A1
The present invention relates to the use of nitric oxide releasing derivatives of paracetamol for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies.  
WO/2010/108001A3
Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.  
WO/2010/108001A2
Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.  
WO/2010/106295A1
The invention relates to decorin for increasing muscle mass, in particular in the treatment of muscular dystrophies.  
WO/2010/104024A1
Disclosed is a piperazine compound represented by general formula (I) or a salt thereof. [In the formula, R1 represents an alkyl group having 1 to 6 carbon atoms; R2 represents any one selected from a hydroxy group, an alkyl group having...  
WO/2010/095663A1
Disclosed is a compound represented by formula (I) or a salt thereof, which has GPR 119 agonist action and excellent medicinal effects useful for prevention/treatment of diabetes, adiposis and the like. In the formula, P represents a sub...  
WO/2010/092966A1
Disclosed is a novel compound having P2X3 or P2X2/3 receptor antagonistic effect. Specifically disclosed is a compound represented by formula (I). (In the formula, (a) Ra and Rb combine together to form =Z, and Rc is a group represented...  
WO/2010/093322A1
The present invention relates to methods for identifying therapeutic agents capable of modulating the activity of the IGF2 repressor ZBED6 for use in growth promotion,wound healing, angiogenesis, inhibition of muscle wasting, and treatme...  
WO/2010/093784A2
The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. I...  
WO/2010/093784A3
The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. I...  
WO/2010/087313A1
Disclosed is a novel neurite elongation stimulator. The neurite elongation stimulator comprises a compound represented by general formula (1) as an active ingredient. In general formula (1), R1 to R3 independently represent a hydrogen a...  
WO/2010/086040A1
Compounds of formula (I) wherein R1, R2, R3, R4, R5, L1, L2, m, and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/087244A1
A novel low-molecular compound having an immunosuppressive action. The compound is a compound having general formula (I) or a pharmacologically acceptable salt thereof. [In the formula, the substituents are defined as shown below: R1 and...  

Matches 701 - 750 out of 18,775